Cedars-sinai Medical Center

Mitest Health LLC

Marla C Dubinsky

Stephan R Targan

Jerome I Rotter

Kent D Taylor

Dermot McGovern

Dermot P Mcgovern

Carol J Landers

Ling Mei

Corey A Siegel

Lori S Siegel

This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.

Diagnosis and treatment of inflammatory bowel disease

The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD.

Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease

The present invention relates to methods of prognosing responsiveness to anti-TNF&#x3b1; therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF&#x3b1; therapy in an individual diagnosed with IBD.

Methods of determining responsiveness to anti-TNF&#x3b1; therapy in inflammatory bowel disease

A system and method for predicting medical outcomes of patients having a variety of diseases, and communicating these predicted outcomes to the patients. The system and method incorporates a plurality of variables and available medical treatments and/or therapies that are available to a patient. All of the variables and treatments are analyzed to predict medical outcomes without treatment, and with each of the plurality of available treatments. The system includes a graphical user interface for inputting the variables and the treatment options. This graphical user interface can comprise a plurality of toggle switches for manipulating each variable as desired. The graphical user interface can display a risk of complication of a disease, both with and without treatment, to a patient, thereby improving communication to the patient and providing healthcare providers and professionals with a procedure and system by which medical outcomes may be predicted and readily communicated to patient.

System and method for communicating predicted medical outcomes

Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease

The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.

Growing community of inventors

Los Angeles, CA, United States of America

Marla C Dubinsky